1474-1480.
S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene
dilution of 1:100. The titer of each serum was calculated as the last serum dilution yielding 1 a specific optical density higher than the cutoff value. 2
The amount of total antigen-specific IgA present in bronchoalveolar and in nasal lavages 3 (BAL and NAL respectively) was also determined by ELISA. Antibody titers were 4 estimated as the reciprocals of the last sample dilution giving an absorbance (A 450 ) value 5 above the cut-off. To compensate for potential variations in the efficiency of recovery of 6 secretory antibodies between animals, the results were normalized according to the total 7
IgA content of the sample. Thus, results were expressed as ELISA Units (EU), namely the 8 endpoint titer of antigen-specific IgA divided by the total concentartion in ug of the IgA 9 present in the sample (23, 24) . To establish the IgA standard curve, plates were coated with 10 anti-mouse IgA (Sigma) and further incubated with serial dilution of purified mouse IgA 11 (Sigma). As secondary antibody, HRP-conjugated goat anti-mouse IgA (ICN Biomedicals, 12
Inc., Aurora, OH) was used; plates were developed as described above. For calculation 13 purposes samples negative for SOD-specific IgA were assigned an arbitrary titer of the 14 lowest dilution measured. 15
16
Cell-mediated immune responses. Mice were euthanized fourteen days after the last 17 immunization and spleens were aseptically removed. The spleens were used to prepare 18 single-cell suspensions by mechanical disaggregation and the erythrocytes were lysed using 19 ACK buffer. Cells were later washed with RPMI medium (19) . Then, the splenocytes were 20 resuspended at a concentration of 4x10 5 viable cells/well in 96-well flat-bottom plates for 21 culturing at 37°C with 5% CO 2 in presence of one of the following stimulants: 10 µg/ml 22 CBPs, 4 µg/ml purified rSOD, 2,5 µg/ml Concanavalin A or no additive (unstimulated 23 control). The cells were cultured in complete RPMI for 72 h and pulsed for 8 h with 0.4 µCi
of 3 H-thymidine (50 µCi/mmol; Amersham. UK) per well. The radioactivity incorporated 1 into the DNA was measured using a scintillation counter. Results were expressed as mean 2 of counts per minute of triplicate cultures from a cell pool obtained from each group (five 3 mice per group). 4 5 Cytokine assays. Cell suspensions of spleens from five control or immunized mice in 6 RPMI medium were plated at 2x10 5 cells/well in flat-bottom micro-well plates (Nunc, 7
Roskilde, Denmark). The cells were stimulated in vitro with either rSOD 0.4 µg/ml or 5 8 µg/ml CBPs, or medium alone, and incubated at 37°C under 5% CO 2 . After 48 h of culture, 9 supernatants were taken and stored until use at -80°C. To measure the production of IFN-γ, 10 IL-4 and IL-10 an antigen-capture ELISAReady-SET-Go! Kit (eBioscience, San Diego, 11 CA) was used. Every experiment was performed in triplicate, and the cytokine 12 concentration from supernatants was calculated using a linear-regression equation from the 13 absorbance values of the standards 14
15
Cytotoxicity assay. The cytotoxicity assay was carried out as described before (25) . 16 Briefly, stimulator cells were prepared by infecting J774.A1 macrophages with live B. 17 abortus strain RB51-SOD at a ratio of 1:100 (cells to RB51-SOD) and incubated for 5 h in 18 RPMI supplemented with 10% heat-inactivated fetal bovine serum (FBS). Then, 19 extracellular bacteria were rinsed away with RPMI containing 50 µg/ml of gentamicin. 20
Macrophages were scraped off and centrifuged at 200 g for 5 min cells were then 21 suspended and incubated for 45 min in 5 ml of RPMI supplemented with 35 µg/ml of 22 mitomycin C. After incubation, the cells were washed by centrifugation with RPMI 23 supplemented with 5% FBS. The previously pulsed antigen presenting cells and the
lymphocytes of immunized mice were distributed to wells of 24-well cell culture plates 1 (Corning) in a 10:1 ratio, and incubated at 37°C with 5% CO 2 for 5 days in order to 2 generated specific cytotoxic T lymphocytes (CTL) (effector lymphocytes). To test the 3 cytotoxic activity against target cells expressing SOD antigen, effectors and target cells (B. 4 abortus SOD/RB51-infected J774.A1 macrophages which were not treated with mitomycin 5 C) were incubated for 16 h at 37°C at 50:1, 10:1, 5:1, and 2.5:1 effector:target ratios. 6
Specific cell lysis was determined by a fluorimetric assay using CytoTox-ONE™ (Promega 7 Table 1 .The log 10 units of protection were calculated by subtracting the 18 mean log 10 CFU for the experimental group from the mean log 10 CFU for the corresponding 19 control group. 20
Statistical analysis. The data derived from the lymphocyte proliferation, detection of 22 cytokine, cytotoxicity,and evaluation of the level of antibody were analyzed using the 23
[10] statistically significant). The data derived from the protection experiment were analyzed 1 using the two way ANOVA test and Sidak's multiple comparisons test with a confidence 2 interval of 95% (α = 0.05). pcDNA-SOD or pcDNA-SOD co-administered with BPPcysMPEG resulted in detectable 12 titers of SOD-specific IgG by day 15, which sustainably increase until the last sampling on 13 day 45. The response in these two groups was significantly (P < 0.001) different as 14 compared to the values of animals receiving PBS, pcDNA3.1 or pcDNA/BPPcysMPEG 15 (i.e. negative control groups). When mice were immunized with pcDNA-SOD alone, we 16 observed that day 15, 30 and 45 the SOD-specific IgG antibody titer was significant lower 17 than in animals from the pcDNA-SOD/BPPcysMPEG group (P < 0.01 day 15 and P < 18
day 30 and 45 respectively). 19
Then, SOD-specific IgG isotypes were analyzed (IgG1 and IgG2a). Significantly 20 increased titer of SOD-specific IgG1 ( SOD IgG1, as compared to the negative control groups (P < 0.001). The value for SOD-1 specific-IG2a (Fig. 1C ) titers in sera from the pcDNA-SOD/BPPcysMPEG group was 2 significantly increased in samples taken on day 15, 30 and 45 post priming, as compared to 3 those from the negative control groups (P < 0.001). The sera from mice immunized with 4 pcDNA-SOD/BPPcysMPEG at day 30 and 45 also showed significantly higher titers of 5 anti-SOD IgG2a, as compared to mice immunized with pcDNA-SOD (P < 0.05 and P < 6 0.001 respectively). 7
To evaluate the mucosal immune responses stimulated in vaccinated animals, the 8 SOD-specific SIgA response was determined in BAL and NAL. As demonstrated in Fig. 2 , 9 mice immunized with pcDNA-SOD or pcDNA-SOD/BPPcysMPEG showed significantly 10 higher levels of SOD-specific mucosal IgA in both BAL ( Fig. 2A) and NAL (Fig. 2B) as 11 compared to negative control mice receiving PBS, pcDNA3.1 or pcDNA3.1/BPPcysMPEG 12 (P < 0.01). Mice immunized with pcDNA-SOD/BPPcysMPEG also showed significantly 13 higher SIgA levels in BAL and NAL, as compared to animals immunized with pcDNA-14 SOD (P < 0.01). 15 16 Cellular immune responses. In order to evaluate the induction of cellular-mediated 17 immunity, we first analyzed the proliferative response on splenocytes. As shown in Fig. 3,  18 following i.n. immunization with either pcDNA-SOD or pcDNA-SOD/BPPcysMPEG, a 19 significant induction of proliferative responses to rSOD and CBPs was observed (P < 0.001 20 as compared to mice in the negative control groups). Responses from splenocytes of mice 21 immunized with pcDNA-SOD/BPPcysMPEG were also significantly higher than in 22 animals vaccinated with pcDNA-SOD alone after restimulation with either rSOD (P <
[12] 0.001) or CBPs (P < 0.01). Only low levels of spontaneous proliferation were observed 1 when testing cells obtained from mice in the control groups. 2
The cytokine profiles of supernatants from cell cultures of spleen cells from the 3 pcDNA-SOD or pcDNA-SOD/BPPcysMPEG immunization groups restimulated with 4 rSOD showed significantly higher levels of IFNγ (P < 0.001 and P < 0.01, respectively) 5 than the negative control groups (Fig. 4A) . Cells from animals immunized with pcDNA-6 SOD also exhibited a significantly higher production of IFNγ than those from pcDNA-7 SOD/BPPcysMPEG immunized mice (P < 0.01). In contrast, significant production of IL-4 8 (P < 0.001) was only observed in the supernatant fluids from cultures of splenocytes 9 derived from pcDNA-SOD/BPPcysMPEG immunized mice when compared to pcDNA-10 SOD or cells from the negative control groups (Fig. 4B) . 11 12 SOD-specific cytotoxic response. DNA immunization has been shown to be effective in 13 inducing CTLs (26). Therefore, the induction of SOD-specific CTLs in pcDNA-SOD or 14 pcDNA-SOD/BPPcysMPEG immunized mice was evaluated and compared to responses in 15 mice receiving PBS, pcDNA3.1 or pcDNA3.1/BPPcysMPEG (Fig 5) . Specific lysis of 16 RB51-SOD-infected J774A1 macrophages was only observed at effector/target ratios of 5:1 17 or higher using cells from mice immunized with pcDNA-SOD or pcDNA-18 SPD/BPPcysMPEG (P < 0.001). Cytotoxic responses were significantly higher at rations 19 5:1 to 50:1 using cells from mice immunized with pcDNA-SPD/BPPcysMPEG compared 20 with cells obtained from the mice immunized with pcDNA-SOD (P < 0.001). 21
22
Protection experiments. Four weeks after the last vaccination, mice were challenged by 23 intraperitoneal injection of the virulent B. abortus 2308 strain and euthanized 15 days later [13] to determine the number of CFU in their spleens (Table 1) . Data from two independent 1 protection experiments indicated that immunization with pcDNA-SOD or pcDNA-2 SOD/BPPcysMPEG induced a significant degree of protection (2.73 and 3.29 log-unit 3 increase in protection, respectively), as compared to the PBS control group (α = 0.05). In 4 comparison, vaccination with live B. abortus strain RB51 induced 3.55 log of protection. 5
Furthermore, immunization with pcDNA-SOD/BPPcysMPEG induced a higher degree of 6 protection against challenge (1.13 log increase of protection) compared to the pcDNA-SOD 7 group (α = 0.05). 
12
Mucosal surfaces are the portal of entry for Brucella species, both in humans and 13 animals. Therefore, large epithelial surfaces, such as the respiratory, intestinal and 14 urogenital tract, need to be protected against penetration to prevent systemic dissemination 15 to target organs. This has led to the concept that a successful vaccine should not only be 16 able to trigger agent-specific immunity at a systemic level (27), but also an efficient local 17 mucosal (28). Unfortunately, soluble antigens administered via mucosal route are usually 18 very poorly immunogenic (29). Thus, different strategies have been developed to increase 19 immunogenicity, among them the use of mucosal adjuvants (30, 31). BPPcysMPEG was 20 proven to be an efficient compound to promote immune responses at systemic and mucosal 21 levels when co-administered with a vaccine antigen (23, (32) (33) (34) . 22
There is sufficient experimental evidence supporting that ability of pcDNA-SOD, a 23 plasmid containing the Brucella Cu,Zn SOD encoding gene, to promote immune protection immunization with pcDNA-SOD appears to promote a Th1-biased immune response (19). 9
At a mucosal level, i.n. immunization with pcDNA-SOD/BPPcysMPEG resulted in the 10 induction of antigen-specific SIgA in both BAL and NAL. 11
As intracellular organism, protection against Brucella infection requires cell-12 mediated immunity, which includes IFN-γ producing CD4 + T cells and CD8 + T 13 lymphocytes (37). Splenocytes from both pcDNA-SOD and pcDNA-SOD/BPPcysMPEG 14 immunized mice showed increased rSOD-specific proliferative responses, as well as 15 production of IFN-γ, which was more abundant in pcDNA-SOD vaccinated mice. 16
Significantly increased secretion of IL-4 was only observed in splenocytes derived from 17 mice immunized with pcDNA-SOD/BPPcysMPEG. On the other hand, re-stimulated 18 splenocytes from both pcDNA-SOD and pcDNA-SOD/BPPcysMPEG immunized mice 19 showed a weak CBPs-specific proliferative response; it can be explained by a low level 20 expression of SOD in the CBPs when compared to the total protein content. Thus, pcDNA-21 SOD preferentially stimulates Th1 responses (19), whereas the inclusion of BPPcysMPEG 22 in the formulation resulted in stimulation of a more balanced Th1/Th2 response.
[15]
As mentioned above, CD8 + T cells with cytotoxic capacity seem to play a key role 1 against Brucella spp. persistent infection (38-40). Thus, we performed a comparative 2 evaluation of the capacity to induce a cytotoxic T lymphocyte response from pcDNA-SOD 3 when administered alone or together with BPPcysMPEG. Both vaccine formulations 4 promoted cytotoxic responses, however, the strongest response was observed with the 5 BPPcysMPEG adjuvanted formulation. This is in agreement with previous studies 6 demonstrating that BPPcysMPEG induces maturation of CD8alpha + and CD8alpha [29] 
